Improvements in patient-reported treatment satisfaction with teriflunomide: results from the phase 4 teri-pro study

P. Rufi[4], **R. Gold[1],** B. Khatri[2], S. Cavalier[3], K.R. Edwards[5]
[1]*St Josef Hospital, Ruhr University Bochum, Germany*
[2]*The Regional MS Center, Center for Neurological Disorders, Wheaton Franciscan Healthcare, USA*
[3]*Sanofi Genzyme, Neurology, USA*
[4]*Sanofi Genzyme, Neurology, France*
[5]*Multiple Sclerosis Center of Northeastern New York, Neurology, USA*

INTRODUCTION: Teriflunomide is a once-daily oral immunomodulator for relapsing-remitting MS. The global, phase 4 study, Teri-PRO (NCT01895335), examined patient-reported outcomes, and the effectiveness, safety, and tolerability of teriflunomide treatment in routine clinical practice. METHODS: Patients with relapsing forms of MS received teriflunomide 7 mg or 14 mg for 48 weeks, per local labeling. The primary outcome was Global Satisfaction at Week (W) 48, measured using the Treatment Satisfaction Questionnaire for Medication (TSQM, v1.4). TSQM scores were measured at baseline (for patients switching from prior disease-modifying therapy [DMT]), and at W4 and W48/end of treatment (all patients). RESULTS: For 1000 treated patients, mean (SD) age was 47.1 (11.0) years; mean time since first MS symptoms was 13.2 (9.5) years. Mean (95% CI) TSQM scores were similar between W4 and W48: Global Satisfaction 72.3 (71.0,73.6)/68.2 (66.4,70.0); Side Effects 88.4 (87.2,89.7)/84.1 (82.5,85.7); Convenience 92.3 (91.6,93.1)/90.4 (89.4,91.3); Effectiveness 67.1 (65.8,68.4)/66.3 (64.7,67.9). In 594 patients who switched from a prior DMT within 6 months, improvements in all TSQM subscales were observed from baseline to W4, and maintained at W48 (*P* CONCLUSIONS: Results from Teri-PRO showed high levels of treatment satisfaction with teriflunomide at W4 and W48 across all TSQM domains. Patients switching to teriflunomide from other DMTs reported a sizeable increase in treatment satisfaction at W48 vs baseline. Previously presented at ECTRIMS 2016.Study supported by Sanofi Genzyme.